Propofol, Triglycerides, and Acute Pancreatitis: A Multicenter Epidemiologic Analysis

Area of Science:

• Critical Care Medicine
• Pharmacology
• Gastroenterology

Background:

• Propofol is a first-line sedative for mechanically ventilated adults.
• Propofol can elevate triglyceride levels, a risk factor for pancreatitis.
• The association between propofol, hypertriglyceridemia, and acute pancreatitis is not well-defined.

Purpose of the Study:

• To determine the clinical impact of propofol infusion on triglyceride levels and acute pancreatitis incidence.
• To investigate the association between propofol, hypertriglyceridemia, and pancreatitis.
• To identify risk factors for pancreatitis in patients receiving propofol.

Main Methods:

• Observational, multicenter study of adults requiring mechanical ventilation and continuous propofol infusion (≥24 hours).
• Primary outcomes included hypertriglyceridemia (>400 mg/dl) and acute pancreatitis frequency.
• Analysis of clinical impact of elevated triglycerides and pancreatitis risk factors.

Main Results:

• Of 11,828 patients, 33.2% had triglyceride levels measured; 21.7% developed hypertriglyceridemia.
• Acute pancreatitis occurred in 1.2% of patients, significantly more frequent in those with hypertriglyceridemia (3.2% vs. 0.7%).
• Each 100 mg/dl triglyceride increase was linked to an 11% higher pancreatitis risk; propofol dose was not associated.

Conclusions:

• Acute pancreatitis is uncommon with propofol infusion but linked to hypertriglyceridemia.
• Hypertriglyceridemia frequently necessitates switching to alternative sedatives.
• The pathophysiology of pancreatitis in this context is multifactorial, requiring further investigation for optimal management.